ATE497969T1 - Zyklische angiotensinanaloga - Google Patents
Zyklische angiotensinanalogaInfo
- Publication number
- ATE497969T1 ATE497969T1 AT07808529T AT07808529T ATE497969T1 AT E497969 T1 ATE497969 T1 AT E497969T1 AT 07808529 T AT07808529 T AT 07808529T AT 07808529 T AT07808529 T AT 07808529T AT E497969 T1 ATE497969 T1 AT E497969T1
- Authority
- AT
- Austria
- Prior art keywords
- analogs
- agonistic
- ang
- cyclised
- antagonistic activity
- Prior art date
Links
- 108010064733 Angiotensins Proteins 0.000 title abstract 4
- 102000015427 Angiotensins Human genes 0.000 title abstract 3
- 230000001270 agonistic effect Effects 0.000 abstract 2
- 230000003042 antagnostic effect Effects 0.000 abstract 2
- 206010020772 Hypertension Diseases 0.000 abstract 1
- PVHLMTREZMEJCG-GDTLVBQBSA-N Ile(5)-angiotensin II (1-7) Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 PVHLMTREZMEJCG-GDTLVBQBSA-N 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 108010027713 angiotensin II (1-8) Proteins 0.000 abstract 1
- 239000002416 angiotensin derivative Substances 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 230000002797 proteolythic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/14—Angiotensins: Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/25—Peptides having up to 20 amino acids in a defined sequence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Separation Of Suspended Particles By Flocculating Agents (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/NL2006/000414 WO2008130217A1 (en) | 2006-08-08 | 2006-08-08 | Cyclic angiotensin analogs |
| PCT/NL2007/050396 WO2008018792A2 (en) | 2006-08-08 | 2007-08-07 | Cyclic angiotensin analogs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE497969T1 true ATE497969T1 (de) | 2011-02-15 |
Family
ID=37809189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07808529T ATE497969T1 (de) | 2006-08-08 | 2007-08-07 | Zyklische angiotensinanaloga |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8835375B2 (de) |
| EP (1) | EP2057184B1 (de) |
| CN (1) | CN101573373B (de) |
| AT (1) | ATE497969T1 (de) |
| AU (1) | AU2007282221B2 (de) |
| CA (1) | CA2660208C (de) |
| DE (1) | DE602007012443D1 (de) |
| DK (1) | DK2057184T3 (de) |
| NZ (1) | NZ574876A (de) |
| WO (2) | WO2008130217A1 (de) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2163259B1 (de) * | 2008-09-12 | 2012-06-13 | Charité-Universitätsmedizin Berlin (Charité) | Verwendung eines Ang-(1-7)-Rezeptorantagonisten bei akuter Lungenverletzung |
| HUE026131T2 (en) | 2008-12-29 | 2016-05-30 | Trevena Inc | Beta-arresin effector and preparations and methods for their use |
| EP2267003A1 (de) | 2009-06-24 | 2010-12-29 | Applied NanoSystems B.V. | Biologisch hergestellte cyclische Affinitätsmarker |
| EP2455388A1 (de) * | 2010-11-23 | 2012-05-23 | LanthioPep B.V. | Neuartige Rezeptoragonisten von Angiotensin des Typs 2 (AT2) und Verwendungen dafür |
| EP2578599A1 (de) * | 2011-10-07 | 2013-04-10 | LanthioPep B.V. | Cyclische Analoga von GLP-1 und GLP-1-verwandten Peptiden |
| CN104168907A (zh) | 2012-01-31 | 2014-11-26 | 特维娜有限公司 | β-抑制蛋白效应器及其组合物与使用方法 |
| CN104394878A (zh) * | 2012-02-10 | 2015-03-04 | 塔瑞克斯制药有限公司 | 用于治疗周围血管疾病的组合物和方法 |
| WO2013130775A1 (en) | 2012-03-01 | 2013-09-06 | Dizerega, Gere, S. | Methods for treating patients undergoing multi-cycle chemotherapy |
| WO2013154983A1 (en) | 2012-04-09 | 2013-10-17 | Rodgers Kathleen E | Molecular markers of endothelial dysfunction in gestational diabetes |
| EP2849773A1 (de) | 2012-05-14 | 2015-03-25 | University of Southern California | Verfahren zur begrenzung der entwicklung einer hautwunde |
| US8557958B1 (en) * | 2012-06-18 | 2013-10-15 | Tarix Pharmaceuticals Ltd. | Compositions and methods for treatment of diabetes |
| WO2014021942A1 (en) | 2012-08-01 | 2014-02-06 | University Of Southern California | Methods for limiting development of neurodegeneration |
| US20150246093A1 (en) * | 2012-09-17 | 2015-09-03 | Tarix Pharmaceuticals Ltd. | Oral formulations of angiotensin |
| US8633158B1 (en) * | 2012-10-02 | 2014-01-21 | Tarix Pharmaceuticals Ltd. | Angiotensin in treating brain conditions |
| EP2968441A1 (de) | 2013-03-15 | 2016-01-20 | University of Southern California | Verfahren zur behandlung von multipler sklerose |
| AU2014233185B2 (en) | 2013-03-15 | 2018-03-15 | University Of Southern California | Methods, compounds, and compositions for the treatment of angiotensin-related diseases |
| EP3003345A4 (de) * | 2013-05-24 | 2017-03-01 | Tarix Pharmaceuticals Ltd. | Angiotensinpeptide bei der behandlung von marfan-syndrom und verwandten erkrankungen |
| LT3607962T (lt) * | 2013-12-18 | 2026-01-12 | The George Washington University, A Congressionally Chartered Not-For-Profit Corporation | Vien tik angiotenzinas ii arba derinyje, skirtas hipotenzijos gydymui |
| CA2938986A1 (en) | 2014-02-07 | 2015-08-13 | Trevena, Inc. | Crystalline and amorphous forms of a beta-arrestin effector |
| US9333233B2 (en) | 2014-02-25 | 2016-05-10 | Tarix Pharmaceuticals Ltd. | Methods and compositions for the delayed treatment of stroke |
| US9611293B2 (en) | 2014-05-19 | 2017-04-04 | Trevena, Inc. | Synthesis of beta-arrestin effectors |
| US10183055B2 (en) | 2014-07-21 | 2019-01-22 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Ang-(1-7) derivative oligopeptides for the treatment of pain and other indications |
| EP3171886A4 (de) * | 2014-07-21 | 2018-01-24 | The Arizona Board of Regents On Behalf of the University of Arizona | Ang-(1-7)derivat-oligopeptide und verfahren zur verwendung und herstellung davon |
| WO2021023698A1 (en) | 2019-08-02 | 2021-02-11 | Lanthiopep B.V | Angiotensin type 2 (at2) receptor agonists for use in the treatment of cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6028168A (en) * | 1991-08-09 | 2000-02-22 | Winfried Kolbeck | Lanthionine bridged peptides |
| US5504191A (en) * | 1994-08-01 | 1996-04-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide methyl esters |
| SE9700301D0 (sv) * | 1997-01-31 | 1997-01-31 | Astra Ab | New compound |
| AU755943B2 (en) * | 1998-08-13 | 2003-01-02 | University Of Southern California | Methods to increase blood flow to ischemic tissue |
| US6861236B2 (en) * | 2002-05-24 | 2005-03-01 | Applied Nanosystems B.V. | Export and modification of (poly)peptides in the lantibiotic way |
-
2006
- 2006-08-08 WO PCT/NL2006/000414 patent/WO2008130217A1/en not_active Ceased
-
2007
- 2007-08-07 WO PCT/NL2007/050396 patent/WO2008018792A2/en not_active Ceased
- 2007-08-07 US US12/376,606 patent/US8835375B2/en active Active
- 2007-08-07 EP EP07808529A patent/EP2057184B1/de not_active Not-in-force
- 2007-08-07 NZ NZ574876A patent/NZ574876A/en not_active IP Right Cessation
- 2007-08-07 AU AU2007282221A patent/AU2007282221B2/en not_active Ceased
- 2007-08-07 DE DE602007012443T patent/DE602007012443D1/de active Active
- 2007-08-07 CA CA2660208A patent/CA2660208C/en not_active Expired - Fee Related
- 2007-08-07 AT AT07808529T patent/ATE497969T1/de not_active IP Right Cessation
- 2007-08-07 CN CN200780034419.7A patent/CN101573373B/zh not_active Expired - Fee Related
- 2007-08-07 DK DK07808529.7T patent/DK2057184T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008018792A3 (en) | 2008-04-03 |
| NZ574876A (en) | 2011-03-31 |
| US8835375B2 (en) | 2014-09-16 |
| AU2007282221A1 (en) | 2008-02-14 |
| WO2008018792A2 (en) | 2008-02-14 |
| EP2057184A2 (de) | 2009-05-13 |
| WO2008130217A1 (en) | 2008-10-30 |
| CA2660208A1 (en) | 2008-02-14 |
| CN101573373A (zh) | 2009-11-04 |
| CN101573373B (zh) | 2014-04-30 |
| DK2057184T3 (da) | 2011-05-02 |
| AU2007282221B2 (en) | 2010-09-02 |
| US20100055146A1 (en) | 2010-03-04 |
| EP2057184B1 (de) | 2011-02-09 |
| CA2660208C (en) | 2012-05-22 |
| DE602007012443D1 (de) | 2011-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2057184T3 (da) | Cykliske antiotensinanaloge | |
| WO2008075371A3 (en) | T-140 peptide analogs having cxcr4 super-agonist activity for immunomodulation | |
| BR112012017054A2 (pt) | "análogo de peptídeo de oxintomodulina, seu uso, bem como composição farmacêutica" | |
| GT200900304A (es) | "antagonistas ciclicos de peptido cxcr4" | |
| NZ707292A (en) | Activin-actrii antagonists and uses for increasing red blood cell levels | |
| WO2004089396A3 (en) | Anti-fungal peptidomimetics | |
| SI2190473T1 (sl) | Peptid z zmanjšano tvorbo dimerov | |
| CL2007002327A1 (es) | Compuestos derivados de fenil-imidazol sustituido; composicion farmaceutica; y uso en el tratamiento del vhc. | |
| PE20130615A1 (es) | Polipeptidos del receptor de activina variante y uso de los mismos | |
| EP2251348A3 (de) | Peptide und ihre Verwendungen | |
| NZ607892A (en) | Tfpi inhibitors and methods of use | |
| MY151973A (en) | Cyclic depsipeptides | |
| IL192373A (en) | Arginine cyclic peptides and their use in the treatment of fungal infections | |
| NZ599604A (en) | Synthetic myostatin peptide antagonists | |
| CL2007002619A1 (es) | Compuestos derivados de 3-aza-biciclo[4.1.0]heptano; composicion farmaceutica; y uso en el tratamiento de la depresion. | |
| CL2007003672A1 (es) | Compuestos derivados de heteroaril-pirrolidinil-cetona y heteroaril-piperidinil-cetona; composicion farmaceutica; y uso en el tratamiento de la depresion y ansiedad. | |
| WO2009047513A3 (en) | Antagonists of kisspeptin and uses thereof | |
| CL2007002769A1 (es) | Compuestos derivados de sulfonamida; procedimiento de obtencion; composicion farmaceutica; y uso en el tratamiento de la diabetes. | |
| CY1111630T1 (el) | Παραγωγα κυτοκινων | |
| EA202190096A1 (ru) | Композиция, содержащая аналог соматостатина, для радиофармацевтического применения | |
| DE502007002251D1 (de) | Oligopeptide enthaltende dermatologische Zusammensetzungen zur Steigerung der Hautempfindlichkeit | |
| DE602006003063D1 (de) | Tripeptid- und tetrapeptidsulfone | |
| EP4541810A3 (de) | Verbindungen zur induktion von geweberegeneration und verwendungen davon | |
| EP1993597A4 (de) | hTERT-PEPTIDE | |
| WO2010079314A3 (en) | Polypeptides and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |